Singapore will participate in a global clinical trial program to develop a vaccine for dengue. The phase II trial will test the safety and immunogenicity of a candidate dengue vaccine.

Approximately 1,200 subjects will be recruited for this double-blind, randomized controlled study, which will take place at four public hospitals in Singapore – the National University Hospital, Singapore General Hospital, Changi General Hospital and KK Women’s and Children’s Hospital.

Source : MIMS Online.